




Online Advanced Methods for Cost-Effectiveness Analysis

Presentation 1: Analytical Starting Points 1.3: 'Decision rules'



Objectives

- Distinguish between independent programmes and mutually exclusive options
- Appreciate details of cost-effectiveness plane
- Understand dominance and ICERs
- Consider role of cost-effectiveness threshold
- Beware its multiple meanings
- Understand importance of an empirical measure of opportunity cost

Programmes and options

Independent programme

- Essentially the population
- e.g. severe migraine

Mutually exclusion options

- Comparison of all options
- One must be selected

Cost-effectiveness plane

Old treatment dominates

What benefits can be generated from the savings?

New treatment **←**

less effective

New treatment less costly and less effective

What benefits can be generated from the savings?

New treatment

↑ more costly

New treatment more costly and more effective

What other benefits could be generated from those same costs?

New treatment more effective

New treatment dominates

What benefits can be generated from the savings?

New treatment less costly

Examples of mutually exclusive options within independent programmes

Management of angina			Breast screening			<u>Treat</u>	Treatment of HIV		
Optio	on Costs	Effects	Option	Costs	Effects	Option	Costs	Effects	
Α	20,000	8	A 1	10,000	20	Α	30,000	25	
В	30,000	4	B 1	20,000	29	В	56,000	40	
С	50,000	19	C 1	50,000	50	С	78,000	42	
D	60,000	23	D 1	90,000	60	D 1	15,000	62	
E	110,000	20	E 2	40,000	70	E 1	150,000	74	


Dominance

Man	agement of an	gina_		
Option	Costs	Effects		
Α	20,000	8		
В	30,000	4	Dominated: B and E	
С	50,000	19	have lower effects and higher cost than other	
D	60,000	23	options. B and E are removed from	
E	110,000	20	consideration.	

Incremental cost-effectiveness ratios (ICERs)

Breast screening					
Option	Costs	Effects	$\Delta C/\Delta E$		
A	110,000	20	-		
В	120,000	29	1,111		
С	150,000	50	1,429		
D	190,000	60	4,000		
E	240,000	70	5,000		

Making decisions from ICERs



Evidence of opportunity costs


HEALTH TECHNOLOGY ASSESSMENT

VOLUME 19 ISSUE 14 FEBRUARY 2015 ISSN 1366-5278

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold

Karl Claxton, Steve Martin, Marta Soares, Nigel Rice, Eldon Spackman, Sebastian Hinde, Nancy Devlin, Peter C Smith and Mark Sculpher

Cost-effective region of cost-effectiveness plane



Extended dominance


Costs	Effects	AC/AE(1)	A C / A E / 2 \
			Δ C/ Δ E (2)
30,000	25	-	-
56,000	40	1,733	1,733
78,000	42	11,000	ED ←
115,000	62	1,850	2,682
150,000	74	2,917	2,917
	56,000 78,000 115,000	56,000 40 78,000 42 115,000 62	56,000 40 1,733 78,000 42 11,000 115,000 62 1,850

Option C is subject to extended dominance as it has a higher ICER than a more effective programme


More on extended dominance

- Best way to understand this is that, for a given threshold, an option subject to extended dominance can never by cost-effective
- Practical way to identify extended dominance:
 - i. Rank options by costs or effects
 - ii. Exclude dominated options
 - iii. Calculate ICERs for the remaining ones
 - iv. If an option exists that has a higher ICER than a more effective one, it is subject to extended dominance and can be removed
 - v. Recalculate ICERs
- Note that, for Step (iv) above, beware that the ICERs you are comparing with are not subject to change when extendedly dominated options are removed

Cost-effectiveness plane: management of HIV



Efficiency frontier: management of HIV



Summary

- Population/sub-population defines independent programme
- ICERs only relevant where no dominance
- ICERs apply in top right and bottom left quadrants
- Beware the concept cost-effectiveness 'threshold'
- Opportunity costs central in cost-effectiveness analysis